The Dermatologic and Ophthalmic Drugs Advisory Committee ( DODAC ) to the US Food and Drug Administration ( FDA ) has voted unanimously to support the approval of AIN457 ( Secukinumab ), a selective interleukin-17A ( IL-17A ) inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
The DODAC based its recommendation on the safety and efficacy outcomes from 10 psoriasis phase II/III clinical studies which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.
The phase III clinical program for Secukinumab included four placebo-controlled pivotal studies which examined Secukinumab 300 mg and 150 mg in patients with moderate-to-severe plaque psoriasis. In these studies, Secukinumab met all primary and key secondary endpoints, including PASI ( Psoriasis Area and Severity Index ) 75 and 90 and IGA mod 2011 ( Investigator's Global Assessment modified 2011 0/1 responses, showing significant skin clearance at Week 12.
In addition, a majority of Secukinumab-treated patients who achieved PASI 75 response and IGA mod 2011 0/1 at Week 12 maintained the response at Week 52 with continued treatment.
PASI measures the redness, scaling and thickness of psoriatic plaques, and the extent of involvement in each region of the body. Treatment efficacy is assessed by the reduction of the score from baseline ( i.e., a 75% reduction is known as PASI 75 and a 90% reduction is known as PASI 90 ). PASI 90 is a higher standard of skin clearance compared to PASI 75.
Currently available data showed no major safety issues. In the pooled analysis of the placebo-controlled period of the pivotal phase III studies, the incidence of serious adverse events was low and comparable for both doses of Secukinumab and placebo ( 2.0% for both 300 mg and 150 mg vs. 1.7% for placebo ). Commonly reported adverse events observed with Secukinumab were nasopharyngitis, headache, diarrhea, pruritus, and upper respiratory infection.
According to an analysis of surveys conducted of 5,600 patients by the National Psoriasis Foundation ( NPF ) between 2003 and 2011, 52% of patients with mild, moderate and severe psoriasis were dissatisfied with their disease management. Of the patients surveyed, some were receiving no treatment ( 9.4-49.2% ) or were undertreated ( 10.2-55.5% ).
Secukinumab is a first-in-class human monoclonal antibody, being investigated for diseases that affect the immune system. The first IL-17A inhibitor to be reviewed by the FDA for moderate-to-severe plaque psoriasis, Secukinumab has been shown to selectively bind to and neutralize IL-17A, inhibiting the release of pro-inflammatory cytokines ( messenger proteins ).
IL-17A is a key messenger protein involved in the development of plaque psoriasis, and is found in high concentrations in psoriasis skin plaques. Research has shown IL-17A plays an important role in driving the body's immune response in disorders such as moderate-to-severe plaque psoriasis and certain arthritic conditions and may represent a new target for investigational therapies. ( Xagena )
Source: Novartis, 2014